A device designed to remove clots from the brain following an ischaemic stroke, the EmboTrap demonstrated high success rates in restoring blood flow and patients achieved high rates of functional independence, according to ARISE II (Analysis of Revascularisation in Ischaemic Stroke with EmboTrap Device), a new clinical trial published in Stroke.
In the ARISE II study, neurointerventional stroke physicians were able to restore blood flow in 80% of patients treated with EmboTrap device within three passes (with a reperfusion grade of mTICI ≥2b). By the end of the procedure, vessels were opened in 93% of patients. In addition, successful reperfusion was achieved with just a single pass in more than half the patients. At the 90-day follow-up, 67% were functionally independent. Overall, the study successfully met the prespecified endpoint.
“I believe that the ARISE II results demonstrate that EmboTrap can provide an effective treatment option for stroke patients with a large vessel occlusion. In particular, the high rates of complete revascularisation, with over half achieving successful reperfusion in a single pass” described Tommy Andersson, Neurosurgeon and Neuroradiologist at the Karolinska University Hospital, Stockholm.
ARISE II was a multicentre clinical study of 228 patients, conducted to assess the safety and effectiveness of the EmboTrap device, a next-generation stent retriever designed to retrieve a broad range of clot types. Patients eligible for the study had large vessel occlusions (LVO) and moderate to severe neurological deficits within eight hours of symptom onset.
